Rahul Banerjee, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on the rationale and aims of an observational study assessing the feasibility and impact of virtual health coaching and digital monitoring devices on the quality of life (QoL) of patients with relapsed/refractory (R/R) multiple myeloma treated with isatuximab-based therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.